HR-1503 : Became Public Law

Orange Book Transparency Act of 2019

This bill modifies requirements for the Food and Drug Administration (FDA) to list and publish drug patent and exclusivity information. Specifically, the FDA must include on its list certain patent information and must specify each drug exclusivity period that has not concluded.

The holder of an approved drug application must notify the FDA when a listed patent is invalidated by a court or by the Patent Trial and Appeal Board. The FDA must remove invalidated patents from its list, subject to the 180-day drug exclusivity period.

Action Timeline

Action DateTypeTextSource
2021-01-05PresidentBecame Public Law No: 116-290.Library of Congress
2021-01-05PresidentSigned by President.Library of Congress
2020-12-24FloorPresented to President.House floor actions
2020-12-10ResolvingDifferencesMotion to reconsider laid on the table Agreed to without objection.House floor actions
2020-12-10ResolvingDifferencesOn motion that the House agree to the Senate amendment Agreed to without objection. (text: CR H7130-7131)House floor actions
2020-12-10FloorMrs. Dingell asked unanimous consent to take the bill, H.R. 1503 from the Speaker's Table and agree to the Senate amendment. (consideration: CR H7130-7131)House floor actions
2020-12-10ResolvingDifferencesMrs. Dingell asked unanimous consent that the House agree to the Senate amendment.House floor actions
2020-12-08FloorMessage on Senate action sent to the House.Senate
2020-12-07FloorPassed Senate with an amendment by Unanimous Consent. (text of amendment in the nature of a substitute: CR S7242-7243)Senate
2020-12-07DischargeSenate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.Senate
2020-12-07FloorMeasure laid before Senate by unanimous consent. (consideration: CR S7244)Senate
2019-05-09IntroReferralReceived in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.Senate
2019-05-08FloorMotion to reconsider laid on the table Agreed to without objection.House floor actions
2019-05-08VoteOn motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 422 - 0 (Roll no. 187). (text: CR H3486-3487)House floor actions
2019-05-08FloorConsidered as unfinished business. (consideration: CR H3491)House floor actions
2019-05-08FloorAt the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.House floor actions
2019-05-08FloorDEBATE - The House proceeded with forty minutes of debate on H.R. 1503.House floor actions
2019-05-08FloorConsidered under suspension of the rules. (consideration: CR H3486-3488)House floor actions
2019-05-08FloorMs. Eshoo moved to suspend the rules and pass the bill, as amended.House floor actions
2019-05-02CalendarsPlaced on the Union Calendar, Calendar No. 25.House floor actions
2019-05-02CommitteeReported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-47.House floor actions
2019-04-03CommitteeOrdered to be Reported (Amended) by Voice Vote.House committee actions
2019-04-03CommitteeCommittee Consideration and Mark-up Session Held.House committee actions
2019-03-27CommitteeForwarded by Subcommittee to Full Committee (Amended) by Voice Vote .House committee actions
2019-03-27CommitteeSubcommittee Consideration and Mark-up Session Held.House committee actions
2019-03-06CommitteeReferred to the Subcommittee on Health.House committee actions
2019-03-05IntroReferralReferred to the House Committee on Energy and Commerce.House floor actions
2019-03-05IntroReferralIntroduced in HouseLibrary of Congress

Policy Area :

Health
See Subjects
  • Administrative law and regulatory procedures
  • Congressional oversight
  • Drug safety, medical device, and laboratory regulation
  • Food and Drug Administration (FDA)
  • Government information and archives
  • Intellectual property
  • Prescription drugs

Related Bills

See Related Bills